[Juvenile idiopathic arthritis: Part 2. Prognosis and current therapeutic approach]

Graciela Espada1

  • 1Sección de Reumatología Hospital de Niños Dr. Ricardo Gutiérrez. gespada@fibertel.com.ar

Insights

Juvenile idiopathic arthritis prognosis has improved due to earlier recognition and better treatments. Biological agents offer new hope for children with difficult-to-treat arthritis.

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Clinical Medicine

Context:

  • Juvenile idiopathic arthritis (JIA) management has evolved significantly.
  • Earlier diagnosis and treatment strategies have improved patient outcomes.
  • Biological agents represent a major advancement in pediatric rheumatology.

Purpose:

  • To review the current understanding of juvenile idiopathic arthritis prognosis.
  • To discuss predictors of poor outcomes in JIA.
  • To outline contemporary treatment approaches, including biological agents.

Summary:

  • The prognosis for juvenile idiopathic arthritis has markedly improved over the past decade.
  • Earlier disease recognition and understanding of outcome predictors are key factors.
  • Biological agents are crucial for managing treatment-resistant JIA cases.

Impact:

  • Improved treatment strategies enhance the long-term outlook for children with JIA.
  • Understanding JIA predictors allows for personalized and proactive patient care.
  • The integration of biological agents offers effective therapeutic options for refractory cases.

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...